Feltl, D <br/><br/>
Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer.  [electronic resource] 

 -  Neoplasma  2005 
 - 393-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0028-2685 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Combined Modality Therapy<br/>Female<br/>Head and Neck Neoplasms--blood<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms, Squamous Cell--blood<br/>Predictive Value of Tests<br/>Prognosis<br/>Radiotherapy<br/>Transforming Growth Factor beta--analysis<br/>Transforming Growth Factor beta1<br/>Tumor Burden--drug effects